You just read:

Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2

News provided by

Immune Pharmaceuticals Inc.

Oct 27, 2016, 07:00 ET